| Dr Evan S Levine, MD | |
|
598 Danbury Rd, Ridgefield, CT 06877-2718 | |
| (917) 748-8898 | |
| Not Available |
| Full Name | Dr Evan S Levine |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 39 Years |
| Location | 598 Danbury Rd, Ridgefield, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366488538 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 169258 (New York) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 61430 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Sinai School Of Medicine Of New York University | 6709919863 | 34 |
News Archive
Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.
An antiviral compound that wiggles its way into the common cold virus may provide one piece of the solution to halting the infection, say Purdue University scientists.
NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.
LanPercept, a new Marie Curie Initial Training Network funded through the 7th EU Framework Programme, will develop cutting edge techniques to understand vision-language mapping across the life-span in typically and atypically developing populations. New tools and training software will be tested to help disabled and elderly people negotiate the translation between vision and language.
› Verified 8 days ago
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.
An antiviral compound that wiggles its way into the common cold virus may provide one piece of the solution to halting the infection, say Purdue University scientists.
NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.
LanPercept, a new Marie Curie Initial Training Network funded through the 7th EU Framework Programme, will develop cutting edge techniques to understand vision-language mapping across the life-span in typically and atypically developing populations. New tools and training software will be tested to help disabled and elderly people negotiate the translation between vision and language.
› Verified 8 days ago
| Entity Name | Mount Sinai School Of Medicine Of New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023334927 PECOS PAC ID: 6709919863 Enrollment ID: O20100727000609 |
News Archive
Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.
An antiviral compound that wiggles its way into the common cold virus may provide one piece of the solution to halting the infection, say Purdue University scientists.
NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.
LanPercept, a new Marie Curie Initial Training Network funded through the 7th EU Framework Programme, will develop cutting edge techniques to understand vision-language mapping across the life-span in typically and atypically developing populations. New tools and training software will be tested to help disabled and elderly people negotiate the translation between vision and language.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Evan S Levine, MD 170 Lounsbury Rd, Ridgefield, CT 06877-4725 Ph: (917) 748-8898 | Dr Evan S Levine, MD 598 Danbury Rd, Ridgefield, CT 06877-2718 Ph: (917) 748-8898 |
News Archive
Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients.
An antiviral compound that wiggles its way into the common cold virus may provide one piece of the solution to halting the infection, say Purdue University scientists.
NeoVista, Inc., announced today that the U.S. Food and Drug Administration (FDA) had approved the company's "compassionate case" waiver to utilize its novel wet age-related macular degeneration (AMD) treatment on a patient with an advanced form of the disease who did not meet criteria for inclusion into current NeoVista investigational treatment protocols.
LanPercept, a new Marie Curie Initial Training Network funded through the 7th EU Framework Programme, will develop cutting edge techniques to understand vision-language mapping across the life-span in typically and atypically developing populations. New tools and training software will be tested to help disabled and elderly people negotiate the translation between vision and language.
› Verified 8 days ago
Dr. Jonathan Mark Gordon, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 21 South St, Ridgefield, CT 06877 Phone: 203-438-6541 | |
Dr. Cristina Hangwa Hung, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 51 Pheasant Ln, Ridgefield, CT 06877 Phone: 917-755-6040 | |
David B Huang, MD, PHD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 900 Ridgebury Rd # G4, Ridgefield, CT 06877 Phone: 203-791-6650 | |
Saragur M Jyothi, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 580 Barrack Hill Rd, Ridgefield, CT 06877 Phone: 203-431-8836 | |
Dr. Jennifer Beth Rubin, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 21 South St, Ridgefield, CT 06877 Phone: 203-438-6541 | |
Robert L Ruxin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect St, Suite 300, Ridgefield, CT 06877 Phone: 203-438-7339 | |
Dr. Frank A Delli Carpini, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 67 Nutmeg Rdg, Ridgefield, CT 06877 Phone: 203-948-0543 Fax: 203-739-0405 |